Advertisement
UK markets close in 3 hours 59 minutes

  • FTSE 100

    8,084.62
    +39.81 (+0.49%)
     

  • FTSE 250

    19,799.93
    +0.21 (+0.00%)
     

  • AIM

    754.87
    0.00 (0.00%)
     

  • GBP/EUR

    1.1638
    +0.0010 (+0.09%)
     

  • GBP/USD

    1.2437
    -0.0015 (-0.12%)
     

  • Bitcoin GBP

    53,534.94
    +378.12 (+0.71%)
     

  • CMC Crypto 200

    1,434.33
    +10.23 (+0.72%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.73
    -0.63 (-0.76%)
     

  • GOLD FUTURES

    2,327.30
    -14.80 (-0.63%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,195.95
    +58.30 (+0.32%)
     

  • CAC 40

    8,136.30
    +30.52 (+0.38%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen

Keith Speights and Brian Orelli, PhD, The Motley Fool
·4-min read

Inovio Pharmaceuticals (NASDAQ: INO) and Ocugen (NASDAQ: OCGN) are two small biotechs that hope to win regulatory authorizations for COVID-19 vaccines in the not-too-distant future. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how these two COVID-19 contenders stack up against each other. Keith Speights: There are two companies that hope to market COVID-19 vaccines: Inovio and Ocugen.

Continue reading